Project Grant R21AI184087
- The National Institutes of Health's National Institute of Allergy and Infectious Diseases awarded a $2.3 million Project Grant to the University of California, Davis to fund research targeting CD4 T follicular helper cells for enhancing HIV vaccine-induced humoral immunity. The two-year award, issued on May 12, 2021 under the Allergy and Infectious Diseases Research program (CFDA 93.855), will support preclinical studies in rhesus macaques to better understand the immunological mechanisms...
- The National Institute of Allergy and Infectious Diseases (NIAID) has awarded a $781,367 Project Grant under the Allergy and Infectious Diseases Research program (CFDA 93.855) to Weill Medical College of Cornell University. The grant, awarded on January 25, 2024, will support research to define and maximize the impact of CD8+ T-cell selection on the landscape of HIV integration sites. The goal is to optimize strategies for eradicating the persistent reservoir of HIV-infected cells and achieve...
- This Project Grant award from the National Institutes of Health (NIH) Office of Research Infrastructure Programs (CFDA 93.351) aims to develop strategies to prevent or eliminate unwanted immune responses toward adeno-associated virus (AAV)-delivered anti-HIV broadly neutralizing antibodies (bNAbs). The $887,626 award to the University of Miami will fund a 2-year study that enrolls 10 rhesus monkeys to test the efficacy of immunomodulatory drugs, such as rapamycin and ibrutinib, in inducing...
- This Project Grant, awarded by the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research Federal Grant Program (CFDA 93.855), supports research to investigate how the cellular protein SAMHD1 regulates innate immunity and HIV-1 gene expression in primary macrophages. The $769,414 award, with a period of performance from July 2025 to June 2030, aims to reveal the mechanisms by which SAMHD1 inhibits the type I interferon and NF-kB pathways,...
- This federal Project Grant award of $433,125, provided by the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855), supports an exploratory study to develop an effective HIV vaccine. The study aims to enhance the antibody-dependent cellular cytotoxicity (ADCC) activity of natural killer (NK) cells using a novel oral adjuvant in a non-human primate model, building on the RV144 vaccine regimen. The research seeks...
- The U.S. Department of Health and Human Services, National Institutes of Health (NIH) awarded a $750,000 Project Grant under the Trans-NIH Research Support program (CFDA 93.310) to Vanderbilt University Medical Center (VUMC) to fund research on the link between trained immunity, immune complexes, and aging-related conditions in people living with HIV (PLWH). The 5-year project aims to investigate how chronic inflammation driven by the persistent HIV reservoir and co-infections like...
- This federal Project Grant award of $848,839 from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research program (CFDA 93.855), supports research to uncover new mechanisms by which HIV accessory proteins control Natural Killer (NK) cell function. The award to the University of Massachusetts Medical School aims to identify novel HIV-regulated NK cell ligands and characterize the role of specific HIV accessory proteins, such as Nef and...
- This $1,285,304 federal Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research Program (CFDA 93.855) supports research to develop a durable broadly neutralizing antibody (bnAb) response for an HIV vaccine regimen. The project, titled "Enhancing Durability of V3 Glycan Vaccine Responses in Rhesus Macaques", will systematically investigate four key concepts to enhance the durability of the bnAb...
- This $197,366 Project Grant was awarded on March 1, 2025 by the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855). The project aims to identify the molecular mechanisms that control the natural, immune-mediated restriction of X4-tropic HIV virus, which typically emerges only in late-stage HIV disease when the immune system is impaired. The research will utilize primary CD4 T cells, in vivo analyses in...
- The National Institute of Allergy and Infectious Diseases (NIAID) awarded a $1,275,484 Cooperative Agreement titled "An Early Life Multivalent Immunization Strategy for Induction of Neutralization Breadth" to the Weill Medical College of Cornell University. The project aims to develop an early life HIV immunization strategy incorporating multivalent HIV envelope immunogens to drive efficient priming and maturation of B cell responses towards broad neutralization. The 5-year project...
IN VIVO INNATE IMMUNE SENSING OF HIV-1 INFECTION - SUMMARY/ABSTRACT HIV-1 REMAINS A MAJOR PUBLIC HEALTH CHALLENGE WORLDWIDE, WITH 1.3 MILLION NEW INFECTIONS AND OVER 600,000 AIDS- RELATED DEATHS IN 2022. AN EFFECTIVE VACCINE THAT CONFERS LONG-TERM PROTECTION AGAINST INFECTION WOULD BE AN ESSENTIAL TOOL IN ERADICATING AIDS, BUT ALL VACCINE CANDIDATES HAVE BEEN LARGELY UNSUCCESSFUL TO DATE. THIS IS DUE TO THE UNIQUE BIOLOGY OF THE VIRUS AND ITS EXTRAORDINARY ABILITY TO ESCAPE IMMUNE RESPONSES. THE IMMUNE EVENTS IMMEDIATELY FOLLOWING HIV-1 TRANSMISSION HAVE CRITICAL IMPACTS ON THE ENSUING DISEASE COURSE, BUT THE UNDERLYING BIOLOGY HAS PROVEN DIFFICULT TO DETAIL. OVERALL, THE INNATE IMMUNE RESPONSE TO A VIRAL INFECTION CAN ESTABLISH A STATE OF VIRAL RESISTANCE AND CONTRIBUTE TO CONTROLLING VIRUS REPLICATION, BUT IT ALSO INDUCES INFLAMMATION THAT CAN FAVOR VIRAL SPREAD, IMMUNOPATHOLOGY AND DISEASE PROGRESSION. STUDIES OF PROSPECTIVE COHORTS OF VOLUNTEERS AT HIGH RISK OF CONTRACTING HIV-1 HAVE REVEALED THE SEQUENCE OF EVENTS DURING ACUTE INFECTION, INCLUDING THE CYTOKINE STORM INDUCED BY THE INNATE IMMUNE RESPONSES. MECHANISTIC IN VITRO STUDIES HAVE DEMONSTRATED THE CAPACITY OF DIVERSE INNATE IMMUNE SENSORS TO DETECT HIV-1 AND INDUCE CYTOKINE PRODUCTION. HOWEVER, THE RELATIVE CONTRIBUTION OF EACH INNATE IMMUNE CELL TYPE AND SENSING PATHWAY FOLLOWING IN VIVO HIV-1 INFECTION, AND THEIR FUNCTIONAL IMPACT ON BOTH THE VIRUS AND THE HOST, ARE LARGELY UNKNOWN. TO OVERCOME THIS LIMITATION, WE DEVELOPED THE MISTRG MODEL OF MICE REPOPULATED WITH A COMPLETE HUMAN IMMUNE SYSTEM ("HUMANIZED MICE"), INCLUDING MONOCYTES, MACROPHAGES, DENDRITIC CELLS AND NK CELLS THAT ARE ESSENTIAL TO MOUNTING INNATE IMMUNE RESPONSES. MISTRG MICE ARE PERMISSIVE FOR HIV-1 INFECTION AND RECAPITULATE SEVERAL ASPECTS OF THE IMMUNE RESPONSES OBSERVED IN HUMANS, INCLUDING THE CYTOKINE STORM TRIGGERED IN THE FIRST FEW WEEKS AFTER INFECTION. FURTHERMORE, WE HAVE RECENTLY DEVELOPED A HIGHLY EFFICIENT PROTOCOL TO KNOCKOUT GENES FROM THE HUMAN IMMUNE SYSTEM OF MISTRG MICE, PROVIDING GENETIC TOOLS THAT WERE PREVIOUSLY EXCLUSIVE TO CONVENTIONAL MOUSE MODELS. USING THE INNOVATIVE MISTRG MODEL, WE NOW PLAN TO INVESTIGATE THE FUNDAMENTAL IN VIVO MECHANISMS OF THE INNATE IMMUNE RESPONSE TO HIV-1, FOLLOWING INFECTION THROUGH BOTH INTRAVENOUS AND MUCOSAL ROUTES. FIRST, WE WILL IDENTIFY THE CELLULAR SOURCE OF CYTOKINES THAT ARE RELEASED DURING THE ACUTE PHASE OF HIV-1 INFECTION. WE WILL COMPLEMENT THESE DESCRIPTIVE STUDIES WITH FUNCTIONAL DEPLETION EXPERIMENTS, TO DETERMINE HOW EACH CYTOKINE-PRODUCING CELL TYPE AFFECTS THE VIRUS AND THE INFECTED HOST. SECOND, WE WILL USE GENE KNOCKOUT APPROACHES TO DETERMINE THE FUNCTIONAL ROLES OF MEMBRANE-BOUND VERSUS INTRACELLULAR INNATE IMMUNE SENSORS IN THE RESPONSE TO HIV-1. WE HYPOTHESIZE THAT DIFFERENT CELL TYPES CONTRIBUTE TO HIV-1 SENSING IN VIVO, THAT THEY RELY ON DISTINCT SENSORS TO DO SO, AND THAT THEIR CONCERTED RESPONSES FUNCTIONALLY IMPACT THE COURSE OF DISEASE. OUR FINDINGS WILL ADDRESS A SIGNIFICANT KNOWLEDGE GAP, AND MAY INFORM THE RATIONALE DESIGN OF NOVEL INNATE IMMUNE INTERVENTIONS FOR THE PREVENTION OR THERAPY OF HIV-1/AIDS.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | $213.5k | 7/15/25 | ||
| Not listed | $231.8k | 7/29/24 |